Skip to main navigation Skip to search Skip to main content

From Kinase Inhibitors to Multitarget Ligands as Powerful Drug Leads for Alzheimer's Disease using Protein-Templated Synthesis

  • Vanesa Nozal
  • , Alfonso García-Rubia
  • , Eva P. Cuevas
  • , Concepción Pérez
  • , Carlota Tosat-Bitrián
  • , Fernando Bartolomé
  • , Eva Carro
  • , David Ramírez
  • , Valle Palomo*
  • , Ana Martínez*
  • *Corresponding author for this work

Research output: Indexed journal article Articlepeer-review

19 Citations (Scopus)

Abstract

Multitarget directed ligands (MTDLs) are arising as promising tools to tackle complex diseases. The main goal of this work is to create powerful modulating agents for neurodegenerative disorders. To achieve this aim, we have combined fragments that inhibit key protein kinases involved in the main pathomolecular pathways of Alzheimer's disease (AD) such as tau aggregation, neuroinflammation and decreased neurogenesis, whilst looking for a third action in beta-secretase (BACE1), responsible of β-amyloid production. We obtained well-balanced MTDLs with in vitro activity in three different relevant targets and efficacy in two cellular models of AD. Furthermore, computational studies confirmed how these compounds accommodate adequately into the long and rather narrow BACE1 catalytic site. Finally, we employed in situ click chemistry using BACE1 as protein template as a versatile synthetic tool that allowed us to obtain further MTDLs.

Original languageEnglish
Pages (from-to)19344-19354
Number of pages11
JournalAngewandte Chemie - International Edition
Volume60
Issue number35
DOIs
Publication statusPublished - 23 Aug 2021
Externally publishedYes

Keywords

  • Alzheimer's disease
  • BACE1
  • in situ click chemistry
  • multitarget directed ligands
  • protein kinase inhibitors

Fingerprint

Dive into the research topics of 'From Kinase Inhibitors to Multitarget Ligands as Powerful Drug Leads for Alzheimer's Disease using Protein-Templated Synthesis'. Together they form a unique fingerprint.

Cite this